
Sign up to save your podcasts
Or


Part 2: Group B Streptococcus (GBS) What is the evidence for screening all pregnant women with a swab?
One doctor would get the swab on the private system in the UK and another would not
Listen Now.
(Apologies we had a technical issue with this episode where it was unintentionally shortened - now resolved)
Dr Lydia Yarlott and Dr Eliz Kilich discuss the two sides of the coin: To get the screening swab for Group B Streptococcus (GBS) or not. The discussion revolves around why different countries have different policies. GBS is a bacteria carries by around 1 in 4 people and can cause sepsis, pneumonia and meningitis in babies when a mother who carries the bacteria (as part of her normal microflora) inadvertently transfers it to baby during delivery of her baby. It is however rare. We follow up on the previous episode with Professor Kirsty Le Doare, an expert in GBS and a leader in running the trials that will hopefully lead to a GBS vaccine for the public in the future. Thus the discussion follows:
1. What are the benefits of the swab as part of screening and if your country of residence does not offer it as routine, would the hosts consider getting it. Spoiler - one would, one wouldn't
2. What are the risk of the bacteria to the baby and what is the actual numerical risk. How many babies need to be delivered to a mum who carries the bacteria for one of the babies to actually get the disease?
3. Are there any downsides to the antibiotics in labour for GBS given that there will be some people due to screening who get it that may not have needed it? If so is there actual proof? How to we weigh this up against the risk of severe illness to baby?
4. What was the evidence that led to some of the differing recommendations and why can't we do a study now.
By Dr Eliz Kilich and Dr Lydia YarlottPart 2: Group B Streptococcus (GBS) What is the evidence for screening all pregnant women with a swab?
One doctor would get the swab on the private system in the UK and another would not
Listen Now.
(Apologies we had a technical issue with this episode where it was unintentionally shortened - now resolved)
Dr Lydia Yarlott and Dr Eliz Kilich discuss the two sides of the coin: To get the screening swab for Group B Streptococcus (GBS) or not. The discussion revolves around why different countries have different policies. GBS is a bacteria carries by around 1 in 4 people and can cause sepsis, pneumonia and meningitis in babies when a mother who carries the bacteria (as part of her normal microflora) inadvertently transfers it to baby during delivery of her baby. It is however rare. We follow up on the previous episode with Professor Kirsty Le Doare, an expert in GBS and a leader in running the trials that will hopefully lead to a GBS vaccine for the public in the future. Thus the discussion follows:
1. What are the benefits of the swab as part of screening and if your country of residence does not offer it as routine, would the hosts consider getting it. Spoiler - one would, one wouldn't
2. What are the risk of the bacteria to the baby and what is the actual numerical risk. How many babies need to be delivered to a mum who carries the bacteria for one of the babies to actually get the disease?
3. Are there any downsides to the antibiotics in labour for GBS given that there will be some people due to screening who get it that may not have needed it? If so is there actual proof? How to we weigh this up against the risk of severe illness to baby?
4. What was the evidence that led to some of the differing recommendations and why can't we do a study now.